The Missing Piece in Preparing Life Science Companies for Investors

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

One of the most pervasive problems we see across life science entrepreneurial programs is that Entrepreneurs-in-Residence (EIRs) help companies develop executive summaries and pitch decks that emphasize the science and market opportunity. This approach repeats across incubators, accelerators, universities, and entrepreneurial training programs worldwide.

The problem is that the two sides of the table are speaking different languages. The sell side presents science and market potential, while investors and licensing partners evaluate the seven-layer risk stack: market, technical, regulatory, execution, economic, financing, and exit risk. They want to understand which risks have been retired, which remain, and what evidence supports the company’s ability to overcome them.

This is precisely where LSN spends its time preparing companies for global roadshows and RESI partnering events.

We begin with the LSN assessment, which identifies where the company sits within the risk stack, what has been accomplished, and what remains to be de-risked. We then reconstitute the executive summary and pitch deck to speak the language of risk, supported by evidence rather than simply promoting the science and market opportunity.

We also develop a milestone-driven Gantt chart that shows the development milestones already completed and the value created, the one, two, or three critical milestones ahead for the remainder of the current year, and the subsequent development and de-risking milestones planned for years two and three.

The capital ask becomes the financial expression of the de-risking plan. By calculating the cost of the current and future milestones, the company can explain precisely how much capital it needs, what that capital will accomplish, which risks will be retired, and how achieving those milestones is expected to increase the asset’s value.

This is the fundamental distinction between a conventional pitch deck and a de-risked deck. One emphasizes the promise of the science and the size of the market. The other demonstrates a credible, milestone-driven, financed pathway to making that science investable.

That is the missing commercialization discipline LSN brings to the table, and it is what investors and licensing partners are looking for.

Register for RESI JPM 2027

Fundraising Requires More Than a Plan. It Requires Execution. (Part 2) 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Experienced life science executives who have successfully raised capital understand something that first-time fundraisers often underestimate: a successful fundraising campaign is not built around a handful of investor introductions or a series of meetings at industry conferences. It is built around a large, qualified, continuously evolving list of investor and licensing-partner targets, supported by the disciplined execution required to keep that list working throughout the campaign.

Last week, I discussed why fundraising requires both a focused strategy and consistent execution. But there is another critical component that deserves more attention: the target list itself. It is the foundation of the entire campaign, and building, maintaining, and continually replenishing that list is one of the most demanding aspects of raising capital.

At Life Science Nation, we have found that experienced fundraising executives are often the first to recognize the value of our BD Assist program. They have been through the process before. They understand that a serious life science fundraising campaign can take 9–18 months, and that a campaign of that duration needs to begin with approximately 800–1,000 qualified investor and licensing-partner targets.

Just as importantly, they know that the original list will not remain intact. Investors respond, decline, change their investment mandates, move into diligence, or prove to be inappropriate targets. Some relationships advance while others are eliminated from consideration. Throughout this process, new qualified targets must continually enter the pipeline to replace those that have fallen away. The campaign is constantly moving, with prospects entering, advancing, and exiting at different stages.

The target list is not a static spreadsheet. It is the engine that drives the fundraising campaign.

Keeping that engine running requires much more than sending emails. It means identifying investors whose investment theses align with the company’s technology, development stage, financing requirements, and geography. It means researching investment activity, finding the appropriate contacts, developing compelling messaging, canvassing prospects, tracking responses, managing follow-up, and maintaining a steady flow of new opportunities.

Experienced executives know how difficult this is because they have done it themselves. They understand that maintaining a professional fundraising campaign often requires a dedicated full-time resource whose responsibility is to keep the target list accurate, active, and continuously replenished. They also know how tedious and time-consuming that work can become, particularly while managing the scientific, clinical, regulatory, financial, and operational responsibilities of an emerging life science company.

This is the fundamental value proposition of LSN’s BD Assist program. LSN has spent years building and maintaining a global database of investors and licensing partners, developing the market intelligence and processes required to identify appropriate targets and execute sustained fundraising campaigns. BD Assist combines that infrastructure with the daily canvassing, outreach, scheduling, tracking, and follow-up needed to keep a campaign moving forward. Rather than building this capability internally, executives can leverage LSN’s existing database, investor intelligence, and business development team to maintain the campaign engine while they concentrate on running their companies and advancing relationships with interested investors.

The value is not simply that BD Assist takes work off an executive’s desk. It provides access to an established fundraising infrastructure that would otherwise take considerable time, money, and effort to replicate.

Timing: Preparing for RESI JPM

The life sciences industry is now preparing for JPM Healthcare Week, when biotech, medtech, diagnostics, digital health, and investment professionals from around the world will gather to establish new relationships and advance existing ones. RESI JPM provides an important opportunity for early-stage companies to meet investors and licensing partners whose interests align with their development and financing objectives. But experienced fundraisers know that conferences are not standalone fundraising strategies. They are opportunities within a much larger campaign.

The companies that benefit most from RESI are those that arrive with a well-developed target list, know which investors they need to meet, have already begun their outreach, and are prepared to continue those conversations long after the conference concludes.

A meeting at RESI may initiate a relationship, advance an existing discussion, or reveal that an investor is not an appropriate fit. Each outcome provides information that helps refine the target list and determine the next step. Meanwhile, the broader fundraising campaign must continue generating new prospects, new conversations, and new opportunities.

RESI creates access. The continuously replenished target list and the execution behind it turn that access into a sustained fundraising campaign.

For executives who have raised capital before, none of this is new. They know what it takes to build a successful campaign, and they know how difficult it is to keep the engine running for 9–18 months. What LSN offers through BD Assist is the infrastructure, investor intelligence, and dedicated execution capability to help them do exactly that.

Ready to Put Your Fundraising Campaign into Motion?

If you are preparing for RESI JPM or planning a sustained fundraising campaign, LSN’s BD Assist team can help you build, maintain, and continuously canvass the global investor and licensing-partner target list that drives the process.

Because a successful fundraising campaign does not run on meetings alone. It runs on a continuously replenished pipeline of qualified targets.

Get Your LSN Labs Company Assessment Report

Fundraising Requires More Than a Plan. It Requires Execution. 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

For early-stage life science companies, fundraising and partnering are not one-time activities. They require an ongoing, focused effort to identify the right market, communicate a clear opportunity, build relationships, and follow through consistently.

Many companies have the science, the data, and the ambition to move forward, but do not have a dedicated business development resource to manage that work throughout the year. Leadership teams are often balancing scientific progress, regulatory planning, operations, and fundraising at the same time.

Life Science Nation’s BD Assist program was developed to provide hands-on support for companies that need help executing their fundraising and partnering campaigns.

BD Assist is the execution layer of Life Science Nation’s commercialization system. It builds on the work of understanding a company’s readiness, identifying the right investor and licensing-partner market, and creating a Global Target List that can support a focused campaign.

The result is not simply a list of contacts. It is a structured process for moving from market intelligence to outreach, follow-up, and meeting generation.

From target market to active campaign

Every BD Assist engagement begins with an understanding of the company’s goals, financing needs, technology, milestones, and partnering objectives. Life Science Nation then works with the company to refine its narrative and marketing materials so the opportunity can be communicated clearly to the market.

Using Life Science Nation’s investor and licensing-partner intelligence, the BD Assist team helps construct and prioritize a Global Target List of relevant investors and strategic partners. The target list is informed by company-specific attributes as well as investor behavior, helping companies focus their efforts on the market most relevant to their opportunity.

From there, BD Assist supports campaign strategy, personalized outreach, follow-up, and meeting generation. Outreach activity is tracked through the client’s CRM platform, allowing the company to maintain visibility into campaign progress and investor engagement.

This ongoing execution is a key part of the program. A target list has value only when it becomes a disciplined campaign that continues to build relationships and create opportunities over time.

Extending a company’s business development capacity

BD Assist is designed to become an extension of a company’s business development capability.

Rather than providing recommendations for a company to carry out on its own, Life Science Nation helps manage the campaign workflow. This allows company leadership to stay focused on advancing the science, reaching development milestones, and preparing for productive investor and partner conversations.

The program also includes regular strategy discussions and campaign refinement as the company receives feedback from the market. As priorities evolve, BD Assist can help ensure that outreach remains aligned with the company’s current fundraising or partnering objectives.

For companies participating in RESI, BD Assist can also support their partnering activity and help them make the most of the investor and licensing-partner marketplace.

Part of a broader commercialization process

BD Assist is one part of a connected Life Science Nation commercialization system.

The Assessment Engine helps companies understand their evidence, risks, milestones, capital readiness, and investability. LSN Labs helps companies address gaps and prepare for the market. The Investor and Licensing Partner Database provides market intelligence. The Global Target List helps companies identify and prioritize their target market. BD Assist helps execute the campaign. RESI creates opportunities to meet the global investor and licensing-partner community.

For companies seeking investment, licensing opportunities, or strategic collaborations, this creates a more connected path from preparation to market engagement.

Fundraising is not only about finding names. It is about executing a consistent process that helps the right companies connect with the right market at the right time.

To learn more about BD Assist and discuss whether it is a fit for your company, complete the LSN Labs Company Assessment Report.

Apply for LSN Labs Company Assessment Report

Secure Your Dedicated Session and Meeting Space at RESI JPM 2027 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

Every January, J.P. Morgan Healthcare Week transforms San Francisco into the global epicenter of life sciences, bringing together top-tier investors, corporate pharma scouts, and biotech innovators. For organizations seeking a visible, accessible base during the busiest week of the year, RESI JPM 2027 offers prime physical space inside the San Francisco Marriott Marquis.

Life Science Nation (LSN) is opening dedicated session and meeting spaces for booking across Monday, January 11 and Tuesday, January 12, 2027. Spaces can be reserved with flexible scheduling options: available by the hour, half-day, or full-day to accommodate presentations, private investor pitches, workshops, or ecosystem receptions. Additionally, hosting organizations receive official RESI JPM Sponsor status, featuring prominent brand exposure across RESI marketing and promotional channels.

Available Spaces and Layouts: Yerba Buena Ballroom (Lower B2 Level)

Located within LSN’s 17,000+ sq. ft. conference footprint across Salons 9–15:

Private Breakout Salons (Salons 10–15):

  • Size and Capacity: ~800 sq. ft. per room, seating up to 70 attendees.
  • Configuration: Fully enclosed private salons ideal for proprietary pitch sessions, closed-door investor roadshows, regional delegation showcases, or a private executive lounge.

Open Session Stage (Salon 9):

  • Size and Capacity: Open ballroom setting accommodating ~60 attendees.
  • Configuration: Positioned directly alongside the high-traffic partnering floor, maximizing foot traffic and casual walk-ins for open panel discussions and cohort spotlights.

Flexible Booking Windows (January 11–12, 2027)

Spaces are available throughout both in-person conference days:

  • Hourly Rentals: For focused company presentations, quick investor roundtables, or press briefings.
  • Half-Day Blocks (Morning / Afternoon): For structured cohort pitch sessions, seminars, or partner workshops.
  • Full-Day / Multi-Day Buyouts: To establish a dedicated branded headquarters and continuous meeting base right inside JPM week.

Immediate Next Steps

Contact LSN: Reach out directly to salescore@lifesciencenation.com to review specific floor plans, pricing tiers, and associated sponsor marketing packages.

RESI Boston 2026: Your Complete Conference Guide 

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022

Life Science Nation (LSN) is pleased to release the RESI Boston 2026 Program Guide for the upcoming hybrid conference, taking place September 22–23 in person at the Westin Copley Place in Boston, followed by virtual partnering on September 25 and September 28–29.

Held during Biotech Week Boston, RESI brings together early-stage life science companies, active investors, strategic partners, and industry leaders for targeted fundraising and business development conversations. The event features the Innovator’s Pitch Challenge, investor panels, workshops, company showcases, and RESI Partnering, the conference’s purpose-built platform for scheduling one-on-one meetings.

The Program Guide offers a comprehensive look at the RESI Boston agenda, including sessions focused on the Boston biotech ecosystem, therapeutic innovation, pharma partnering, strategic capital, health systems, chronic disease care, family office investing, and impact investing. Attendees can also explore the participating investor, sponsor, exhibitor, and company lineup, along with networking opportunities throughout the event.

With partnering underway and meeting calendars continuing to fill in the final weeks before the conference, RESI Boston offers innovators a valuable opportunity to connect directly with investors and strategic stakeholders shaping the future of healthcare.

View the program guide and register for RESI Boston today.

Register for RESI Boston

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

Life Science Nation’s 2027 RESI conference calendar will connect early-stage life science companies with global investors, pharma partners, and industry leaders across four major life science hubs: San Francisco, Tokyo, Philadelphia, and Boston.

The year begins during JPM week and continues through Asia, BIO International Convention week in Philadelphia, and Boston’s biotech week in September. Each event is designed to help emerging companies build the investor relationships and strategic partnerships needed to move their companies forward.

RESI JPM 2027: January 11–12

San Francisco Marriott Marquis, San Francisco

Registration is now open for RESI JPM 2027.

Held concurrently with JPM Healthcare Week, RESI JPM brings early-stage companies into San Francisco during one of the world’s largest annual gatherings for healthcare investment and business development. The two-day in-person conference will be followed by virtual partnering on January 13, 18, and 19.

Previous RESI JPM conferences have drawn more than 1,000 attendees, including over 600 early-stage life science investors, innovators, and industry experts. For companies raising capital, pursuing strategic partnerships, or preparing for a major financing milestone, RESI offers a focused setting to make the most of the week.

RESI Asia Japan 2027: April 13

ANA InterContinental, Tokyo

RESI Asia Japan launches in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster.

Japan represents one of the life science industry’s most valuable and least accessible markets. Its leading pharmaceutical companies are active licensors and acquirers of external innovation, while the country offers deep clinical development capabilities and a progressive regulatory pathway for regenerative medicine, cell therapy, and gene therapy.

RESI Asia Japan will create a direct bridge between Japan’s world-class science ecosystem and global capital and partnering networks. The event is part of a broader collaboration between Life Science Nation and KBIC focused on strengthening commercialization pathways, entrepreneur education, capital formation, and international business development for Japanese life science companies.

RESI Philadelphia 2027: June 7

Convene, Philadelphia

RESI Philadelphia will take place during BIO International Convention week, complementing the broader industry activity in the city with a dedicated forum for early-stage companies and active investors.

Philadelphia is a leading center for cell and gene therapy, biopharma, medical innovation, and academic research. RESI provides companies and investors attending BIO week with a targeted environment for investor partnering, live pitch opportunities, and conversations that can turn promising science into fundable, strategic opportunities.

Virtual partnering dates will be announced soon.

RESI Boston 2027: September 22

Westin Copley Place, Boston

RESI returns to Boston during biotech week, bringing the global early-stage life science investment community together in one of the world’s most important innovation hubs.

Boston’s unmatched concentration of founders, investors, academic institutions, biotech companies, and strategic partners makes it an essential stop on the RESI calendar. The in-person event will offer targeted partnering, investor panels, educational programming, and the Innovator’s Pitch Challenge for companies seeking to raise visibility and advance fundraising conversations.

Virtual partnering dates will be announced soon.

A Global RESI Run

The 2027 lineup offers companies multiple opportunities throughout the year to engage the Life Science Nation network, deepen relationships with investors and strategic partners, and access new regional markets.

  • RESI JPM: January 11–12, San Francisco
  • RESI Asia Japan: April 13, Tokyo
  • RESI Philadelphia: June 7, Philadelphia
  • RESI Boston: September 22, Boston

Registration is now open for RESI JPM 2027. Register by October 2 to save $900 with Super Early Bird pricing. Learn more at resiconference.com.

Register for RESI JPM 2027

RESI Boston 2026 Innovator’s Pitch Challenge Finalists 

By Max Braht, VP of Business Development, LSN

Max-Braht-Headshot

The Innovator’s Pitch Challenge (IPC) showcases early-stage companies developing breakthrough technologies across key sectors of life science and returns to RESI Boston with more than 65 innovative companies selected to pitch across 20 sessions over two days, September 22–23, 2026.

Each finalist will present to panels of active life science investors and industry leaders in sector-focused sessions spanning biotech, medtech, diagnostics, digital health, and more. The program gives fundraising companies the opportunity to share their technologies, receive practical feedback, and connect directly with investors and strategic partners seeking new opportunities.

For attendees, IPC is a chance to discover emerging companies and hear directly from the founders behind them. Finalists will also be available throughout the event exhibiting, networking, and attendees participating in partnering can schedule one-on-one meetings to continue the conversation.

Join Life Science Nation at RESI Boston during Biotech Week for two full days of company pitches, investor insights, and targeted partnering.

Register for RESI Boston 2026

Meet the RESI Boston Innovator’s Pitch Challenge Finalists: